Contineum Therapeutics, Inc. - 8-K Filing
On June 26, 2026, Contineum Therapeutics held its annual stockholder meeting where three Class II directors were elected with votes for ranging from 20,593,715 to 21,773,559. The appointment of Ernst & Young LLP as the independent registered public accounting firm was also ratified by shareholders. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $CTNM